← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Publicado por Yahoo Finance · Estados Unidos hace 9 h

Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar

MarketBeat

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

 The Motley Fool

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

 MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

 TheStreet

Gold prices break $4,000 as investors brace for crucial test

 Benzinga

Myro (MYRO) Price Prediction: 2025, 2026, 2030

 Stocktwits

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M